Giant Biogene Holding Full Year 2022 Earnings: Revenues Beat Expectations, EPS In Line

Giant Biogene Holding (HKG:2367) Full Year 2022 Results

Key Financial Results

• Revenue: CN¥2.36b (up 52% from FY 2021).
• Net income: CN¥696.0m (down 14% from FY 2021).
• Profit margin: 29% (down from 52% in FY 2021). The decrease in margin was driven by higher expenses.
• EPS: CN¥0.99.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Giant Biogene Holding Revenues Beat Expectations

Revenue exceeded analyst estimates by 7.6%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Personal Products industry in Hong Kong.

Performance of the Hong Kong Personal Products industry.

The company's shares are down 15% from a week ago.

Risk Analysis

Be aware that Giant Biogene Holding is showing 1 warning sign in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.